BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2025 8:16:40 AM | Browse: 137 | Download: 389
 |
Received |
|
2025-05-30 01:41 |
|
Peer-Review Started |
|
2025-05-30 01:41 |
|
First Decision by Editorial Office Director |
|
2025-06-06 03:40 |
|
Return for Revision |
|
2025-06-06 03:40 |
|
Revised |
|
2025-06-12 19:49 |
|
Publication Fee Transferred |
|
2025-06-17 17:14 |
|
Second Decision by Editor |
|
2025-07-18 02:46 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-07-18 07:02 |
|
Articles in Press |
|
2025-07-18 07:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-07 07:27 |
|
Publish the Manuscript Online |
|
2025-08-21 08:16 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Review |
| Article Title |
Integrative cardiovascular disease therapy: Linoleic acid restriction, enhanced external counterpulsation, and emerging nanotherapies
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Joseph Mercola |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Joseph Mercola, Researcher, /, Midwestern University, 555 31st Street, Downers Grove, IL 60515, United States. drm@mercola.com |
| Key Words |
Cardiovascular disease; Atherosclerosis; Integrative therapy; Linoleic acid reduction; Enhanced external counterpulsation; Nanoparticle-facilitated chelation; Metabolic optimization; Residual cardiovascular risk |
| Core Tip |
Cardiovascular disease (CVD) care still leaves a 20 % five-year major adverse cardiovascular event (MACE) risk. This review outlines an integrative, root-cause strategy combining dietary linoleic acid (LA) restriction ( < 5 g/day) to lower oxidized low-density lipoprotein (oxLDL), non-invasive enhanced external counterpulsation (EECP) to boost nitric-oxide–mediated perfusion, and plaque-targeted nanoliposomal chelation to reverse calcification. These scalable, affordable interventions collectively target oxidative stress, endothelial inflammation and plaque instability, offering a realistic roadmap to transform coronary events from commonplace to rare and potentially reshape future CVD management. |
| Publish Date |
2025-08-21 08:16 |
| Citation |
Mercola J. Integrative cardiovascular disease therapy: Linoleic acid restriction, enhanced external counterpulsation, and emerging nanotherapies. World J Cardiol 2025; 17(8): 110163 |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i8/110163.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i8.110163 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
